$DWTX News

Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial

Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

Dogwood Therapeutics Q1 EPS $(0.15), Inline

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2

Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood Therapeutics Announces FDA Acceptance Of IND Application For Development Candidate SP16, Administered IV, For Treatment Of Chemotherapy-Induced Pain And Peripheral Neuropathy

DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate

HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target

DWTX: Financing Secures Funding Through Phase 2b Data Readout

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026